(R)-4-Methyloxazolidin-2-one → (R)-3-{3,5-difluoro-4-[4-(5-methylpyridin-2-yl)piperazine-1-carbonyl]phenyl}-4-methyloxazolidin-2-one
反応式
Br[C:2]1[CH:7]=[C:6]([F:8])[C:5]([C:9]([N:11]2[CH2:16][CH2:15][N:14]([C:17]3[CH:22]=[CH:21][C:20]([CH3:23])=[CH:19][N:18]=3)[CH2:13][CH2:12]2)=[O:10])=[C:4]([F:24])[CH:3]=1.[CH3:25][C@@H:26]1[CH2:30][O:29][C:28](=[O:31])[NH:27]1>>[F:24][C:4]1[CH:3]=[C:2]([N:27]2[C@H:26]([CH3:25])[CH2:30][O:29][C:28]2=[O:31])[CH:7]=[C:6]([F:8])[C:5]=1[C:9]([N:11]1[CH2:16][CH2:15][N:14]([C:17]2[CH:22]=[CH:21][C:20]([CH3:23])=[CH:19][N:18]=2)[CH2:13][CH2:12]1)=[O:10]参加物
3
実験手順
By reaction and treatment in the same manner as in Example 110 and using (4-bromo-2,6-difluorophenyl)[4-(5-methylpyridin-2-yl)piperazin-1-yl]methanone (393 mg) described in Preparation Example 185 and (R)-4-methyloxazolidin-2-one (132 mg) described in Preparation Example 25, the title compound (277 mg) was obtained.
後処理
- customBy reaction and treatment in the same manner as in Example 110